OUR STORY

Tessa Therapeutics is founded on over three decades of research and development by our Scientific Co-Founder, Dr. Malcolm K Brenner, and his team at Baylor College of Medicine. Leveraging the potential of the body’s natural anti-viral immune response as a therapy for cancer treatment, Tessa is emerging with a new approach to cell therapy for hematologic malignancies and solid tumors.

Learn More

OUR SCIENCE

Tessa is combining the unique properties of Virus-Specific T cells (VSTs) and CD-30 Chimeric Antigen Receptors (CD30-CARs) to develop an allogeneic platform technology that gives us the potential to create next-generation cell therapies for the treatment of hematologic malignancies and solid tumors.

Learn More

OUR PIPELINE

Our robust clinical pipeline of autologous and allogeneic cell therapies includes two late-stage clinical studies for Hodgkin lymphoma and nasopharyngeal cancer.

Learn More

OUR OPERATIONS

Our global manufacturing and supply chain capabilities — enhanced by a new commercial-scale cGMP — will enable us to supply next-generation cell therapies that may potentially address the significant needs of the global oncology community.

Learn More
null

Our Story

null

Our Science

null

Our Pipeline

null

Our Operations

Feature News

Tessa at a Glance

200+ Employees Globally

Learn More >>

2 Late-stage Clinical Trials

Learn More >>

Global Site Network

Learn More >>

3 Research & Development Labs

Learn More >>

5 Strategic Partnerships

Learn More >>

Upcoming cGMP Manufacturing Facility

Learn More >>

Global Scientific Advisory Board & Key Opinion Leader Network

Learn More >>

3 Satellite Labs

Learn More >>

Tessa on Twitter

1 month ago
We are pleased to announce that Tessa’s investigational CD30 CAR-T therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA for the treatment of relapsed or refractory classical Hodgkin lymphoma. Read more here: https://t.co/rR5pJMZZ0f https://t.co/Rjp4NxhSau
3 months ago
Dr Ramy Ibrahim, CMO @parkerici discusses some of the cellular #immunotherapy breakthroughs we can anticipate this decade in this interview with our CSO, Dr John Connolly
@hotirishmonkey: https://t.co/0oe9JLMJSl #celltherapy #solvecancer #bioinformatics https://t.co/J3bExyFFuD

Tessa’s Media Channel

In this latest interview, Dr Ramy Ibrahim from Parker Institute for Cancer Immunotherapy discusses some of the cellular immunotherapy breakthroughs we can anticipate this decade.